AVAVA has pioneered two devices
Both employ the core enabling Focal Point Technology™ and Intelliview innovation to unlock multiple clinical indications
The FDA adopted Focal Point Technology™ as a new class of intradermal lasers and granted AVAVA a first‑in‑class regulatory clearance for high energy up to 150mj energy dose.
Both devices are FDA-cleared and deliver a, non-invasive, breakthrough procedure that promotes skin health, treats skin aging, and can safely treat pigmentary disorders. The design inherent in Focal Point Technology™ spares damage to the epidermis by reducing fluence and allows depth control making it safe for use on all skin colors.
The FDA adopted Focal Point Technology™ as a new class of intradermal lasers and granted AVAVA a first‑in‑class regulatory clearance for high energy up to 150mj energy dose.
Both devices are FDA-cleared and deliver a, non-invasive, breakthrough procedure that promotes skin health, treats skin aging, and can safely treat pigmentary disorders. The design inherent in Focal Point Technology™ spares damage to the epidermis by reducing fluence and allows depth control making it safe for use on all skin colors.